Myc-Driven, Primary Mouse Lymphoma Expressing Human Cd22 Are Highly Infiltrated By Syngeneic Immune Cells And Provide A Unique Model To Test Cd22-Targeted Therapies

Background: CD22 has emerged as an attractive target for the treatment of B-cell malignancies because (i) CD22 shows high surface expression on most mature and precursor B-cell malignancies, (ii) it is rapidly internalized after ligand binding, and (iii) it is readily replenished after internalization due to a substantial intracellular pool. CD22 has been engaged therapeutically using CAR-T cells (Frey, 2018), immunotoxins (Wayne, 2018), or Antibody-drug-conjugates (Kantarjian, 2016). Preclinical data, however, has exclusively been generated using immune compromised mice which is a major drawback of current animal models.